JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

Starting Tuesday, CVS Caremark – a major pharmacy benefit manager that serves as a middleman for health insurers, large employers and other payers to manage their prescription drug plans – will stop ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...